Kempen & Co | Jotup

DGAP-News: CureVac Announces Closing of $450 million Follow-on Public Offering of Common Shares

Retrieved on:

Tuesday, February 2, 2021

Finance, Financial services, Companies, CureVac, Tübingen, Evercore, Kempen & Co, CVac, NASDAQ, UBS, Offering, Investment banking

TBINGEN, Germany / BOSTON, USA - February 2, 2021 - CureVac N.V. (Nasdaq: CVAC) ("CureVac" or the "Company"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today the closing of its follow-on public offering of 5,000,000 common shares, at a public offering price of $90.00 per common share, for total gross proceeds of approximately $450 million.

Key Points:

TBINGEN, Germany / BOSTON, USA - February 2, 2021 - CureVac N.V. (Nasdaq: CVAC) ("CureVac" or the "Company"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today the closing of its follow-on public offering of 5,000,000 common shares, at a public offering price of $90.00 per common share, for total gross proceeds of approximately $450 million.
BofA Securities, Jefferies and Evercore ISI are acting as joint book-running managers for the offering.
UBS Investment Bank, Guggenheim Securities, Berenberg and Kempen & Co are acting as passive book-running managers for the offering.
CureVac had its initial public offering on the New York Nasdaq in August 2020.

DGAP-News: CureVac Announces Proposed Public Offering of Common Shares

Retrieved on:

Monday, January 25, 2021

Finance, Money, Financial services, CureVac, Tübingen, Corporate finance, Stock market, Initial public offering, Evercore, Public offering, Kempen & Co, Underwriting

TBINGEN, Germany/ BOSTON, USA - January 25, 2021 - CureVac N.V. (Nasdaq: CVAC) ("CureVac" or the "Company"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today that it intends to offer and sell in an underwritten public offering 5,000,000 common shares.

Key Points:

TBINGEN, Germany/ BOSTON, USA - January 25, 2021 - CureVac N.V. (Nasdaq: CVAC) ("CureVac" or the "Company"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today that it intends to offer and sell in an underwritten public offering 5,000,000 common shares.
In addition, the Company expects to grant the underwriters a 30-day option to purchase up to an additional 750,000 common shares at the public offering price, less underwriting discounts and commissions.
BofA Securities, Jefferies and Evercore ISI are acting as joint book-running managers for the proposed offering.
UBS Investment Bank, Guggenheim Securities, Berenberg and Kempen & Co are acting as the passive book-running managersfor the proposed offering.

Sensorion Launches a Capital Increase by Means of an Accelerated Bookbuild Offering

Retrieved on:

Thursday, September 17, 2020

Biotechnology, Pharmaceutical, Health, Corporate finance, Bookrunner, Initial public offering, Sofinnova, Kempen & Co, Finance, Industries

Invus Public Equities LP and Sofinnova Partners, which are existing shareholders, have indicated an interest to participate in the Reserved Offering at the offering price, up to their prorata.

Key Points:

Invus Public Equities LP and Sofinnova Partners, which are existing shareholders, have indicated an interest to participate in the Reserved Offering at the offering price, up to their prorata.
Jefferies International Limited (Jefferies) is acting as Sole Global Coordinator and Joint Bookrunner in connection with the Reserved Offering.
Bryan, Garnier & Co and Kempen & Co are acting as Joint Bookrunners in connection with the Reserved Offering (together with Jefferies, the "Placing Agents").
Namsen Capital is acting as equity capital markets advisor.

Immunovia Intends to Carry Out a Directed Share Issue Through an Accelerated Book Building Process

Retrieved on:

Thursday, June 4, 2020

Stock market, Finance, Financial economics, Equity securities, Corporate finance, Financial markets, Book building, Vator, Kempen & Co, Short, Share, Stock

STOCKHOLM, June 4, 2020 /PRNewswire/ -- INSIDE INFORMATION: Immunovia AB (publ) ("Immunovia" or the "Company") intends to carry out a directed issue of shares of approximately 15 percent of the issued share capital, with the potential to upsize the transaction, through an accelerated book building procedure (the "Directed Issue").

Key Points:

STOCKHOLM, June 4, 2020 /PRNewswire/ -- INSIDE INFORMATION: Immunovia AB (publ) ("Immunovia" or the "Company") intends to carry out a directed issue of shares of approximately 15 percent of the issued share capital, with the potential to upsize the transaction, through an accelerated book building procedure (the "Directed Issue").
Immunovia has engaged Kempen & Co, Danske Bank and Vator Securities to explore the possibilities to conduct the Directed Issue.
The Board of Directors may decide to extend or shorten the application period and can at any moment decide to terminate the book building process and thus refrain from conducting the Directed Issue.
In connection with the Directed Issue, the Company has undertaken, with customary exceptions, not to issue additional shares for a period of 180 calendar days after closing of the Directed Issue.

argenx announces closing of global offering

Retrieved on:

Monday, June 1, 2020

Finance, Investment banks, Financial services, Wedbush Securities, Money, Euronext, Kempen & Co, Stifel, Nomura, Antibody

The gross proceeds from the global offering were approximately $862.5 million (approximately 784.7 million).

Key Points:

The gross proceeds from the global offering were approximately $862.5 million (approximately 784.7 million).
Stifel, JMP Securities, Wedbush PacGrow, Nomura and Kempen & Co acted as co-managers for the offering.
In addition, argenx announces the listing of and the commencement of dealings in its 4,207,292 new ordinary shares on the regulated market of Euronext Brussels.
argenx is a global immunology company developing antibody-based medicines for patients suffering from severe autoimmune diseases and cancer.

argenx raises $750 million in gross proceeds in a global offering

Retrieved on:

Thursday, May 28, 2020

Finance, Banks, Money, Investment banks, Wedbush Securities, ADSS, Kempen & Co, Autoimmunity, Security, BofA Securities, Immunology, Nomura

Each of the ADSs offered in the offering represents the right to receive one ordinary share, nominal value of 0.10 per share.

Key Points:

Each of the ADSs offered in the offering represents the right to receive one ordinary share, nominal value of 0.10 per share.
J.P. Morgan, Cowen and BofA Securities are acting as joint bookrunning managers for the offering.
Stifel, JMP Securities, Wedbush PacGrow, Nomura and Kempen & Co are acting as co-managers for the offering.
argenx is a global immunology company developing antibody-based medicines for patients suffering from severe autoimmune diseases and cancer.